Parabilis Medicines (PBLS) Q2 2026 earnings summary

Executive summary

• Clinical-stage biopharma focused on Helicon platform for undruggable protein targets, with lead candidate zolucatetide showing promising Phase 1/2 results in desmoid tumors and plans for a Phase 3 trial in 2027.

• Entered a major collaboration with Regeneron in May 2026, including a $50M upfront payment and $75M equity investment, with potential for up to $2.2B in milestones and royalties.

• Completed IPO and concurrent private placement in June 2026, raising $770.5M–$788M net, ending Q2 with $1.1B–$1.12B in cash, cash equivalents, and marketable securities, expected to fund operations into 2030.

• Net losses continue as expected for a clinical-stage company, with a focus on expanding R&D and pipeline development.

• Strengthened leadership with new executive appointments and board member.

Financial highlights

• Collaboration revenue was $0.1M for both the three and six months ended June 30, 2026, reflecting the start of the Regeneron agreement.

• Net loss for Q2 2026 was $52.5M, up from $34.8M in Q2 2025; net loss for the first half of 2026 was $97.8M, up from $73.1M year-over-year.

• Research and development expenses rose 30.7% year-over-year to $39.4M for Q2 2026, and 20.5% to $77.1M for the first half of 2026.

• General and administrative expenses increased 82.3% year-over-year to $11.7M for Q2 2026, and 67.8% to $21.4M for the first half of 2026, driven by headcount, IPO costs, and stock-based compensation.

• Interest income increased to $4.2M in Q2 2026 due to higher cash balances post-IPO.

Outlook and guidance

• Cash, cash equivalents, and marketable securities are expected to fund operations into 2030, but additional capital will be needed for long-term growth and commercialization.

• Anticipates increased expenses as clinical programs expand, especially with planned Phase 3 trial for zolucatetide and further pipeline development.

• Expects collaboration revenue to increase as Regeneron research activities progress.

• Plans to present Phase 1/2 desmoid tumor data at ESMO 2026 and more mature data in Q4 2026.

• Expects to engage FDA in Q4 2026 and initiate Phase 3 trial for desmoid tumors in H1 2027.